Friday 16 February 2018 2:53pm
A Christchurch rheumatologist has won Medicines New Zealand's top prize for research into how increasing dosages of gout medicines can dramatically improve patients’ lives.
Professor Lisa Stamp’s study showed it was safe and effective to increase doses of a crucial drug for managing gout. It provided clear evidence in an area where there was much confusion worldwide.
Gout is the most common form of inflammatory arthritis, affecting tens of millions worldwide.
Stamp was this month awarded the Medicines New Zealand’s Value of Medicines Award. The award came with $20,000 to further her research.
The judges said Stamp’s study would have “a high impact on patient care, especially benefitting Māori, Pacific and renal patients.” The research would also have a big impact internationally, the judges said.
In 2016, a group of international gout experts advised doctors not to use higher doses of the drug. Stamp’s robust clinical study found using higher doses of allopurinol was safe and could prevent ongoing attacks of the painful disease. It could also help stop the disease from progressing to a chronic state in many patients.
In the study, published in the prestigious journal Annals of the Rheumatic Diseases, one group of patients had increased doses, while another group did not. Stamp found the two groups experienced similar rates of side-effects. Those on higher doses of allopurinol had better blood results for a crucial measure of the disease.
Stamp says she will use the prize money for further research on predicting patient responses to allopurinol.
For more information, please contact:
Phone: 027 222 6016
A list of Otago experts available for media comment is available elsewhere on this website.
Electronic addresses (including email accounts, instant messaging services, or telephone accounts) published on this page are for the sole purpose of contact with the individuals concerned, in their capacity as officers, employees or students of the University of Otago, or their respective organisation. Publication of any such electronic address is not to be taken as consent to receive unsolicited commercial electronic messages by the address holder.